MAKING-SCIENCE
22.1.2024 16:01:32 CET | Business Wire | Press release
Making Science, a technology company specialising in innovation and digital acceleration, has today announced the launch of Gauss Cookie Deprecation Impact Tool, the first and only solution on the market designed to measure in real time what impact the loss of third-party cookies will have on companies' conversion rate to sales.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122293551/en/
(Photo: Business Wire)
This innovative tool comes at a key moment for the industry, following the announcement of Google's elimination of third-party cookies, scheduled for the second half of 2024. The Gauss Cookie Deprecation Impact Tool will provide Making Science customers with accurate percentage data to confirm how this loss of information will affect their business. In other words, for the first time, companies will have access to an unprecedented assessment that provides real data on the percentage of users who visit websites and applications without cookies, corroborating the effect on their marketing strategies.
The tool has already yielded very significant data for a selection of Making Science clients, measuring that the absence of third-party cookies will lead to a 30% drop in their conversion rates.
Real-time data thanks to technological innovation
This new platform is essential for companies that want to be prepared for the cookieless transformation of the digital ecosystem. Thanks to technological innovation and high capabilities in data analysis, Making Science will enable organisations to effectively identify how to redesign their marketing strategies, and optimise their performance in the face of this changing landscape.
With this launch, Making Science reaffirms its pioneering position in the development of innovative technological solutions. José Antonio Martínez Aguilar, CEO and Founder of Making Science, comments: "Staying ahead in a constantly changing digital environment is not an easy task, for that, it is essential to bet on innovation every day. Undoubtedly, the key is to have the ability to anticipate and come up with solutions such as Gauss Cookie Deprecation Impact Tool. This solution not only responds to the challenge of the loss of third-party cookies, but also offers companies the opportunity to anticipate and make strategic decisions to face a new landscape based on first-party data".
Gauss, the origin of the cutting edge
This new tool from Making Science is part of Gauss, a suite of technology solutions based on First Party Data and Artificial Intelligence for decision-making in key marketing and sales processes.
About Making Science
Making Science is a digital acceleration company with more than 1200 employees and a presence and technological development in 14 markets: Spain, Portugal, Mexico, Colombia, France, Italy, UK, Ireland, Sweden, Denmark, Norway, Germany, Georgia and USA. As a consulting partner of Local Planet, the world's largest network of independent media agencies, Making Science offers digital, technology and performance marketing services to an international audience. The areas in which Making Science operates are digital marketing and MarTech, software and cloud and artificial intelligence and SaaS, with a firm commitment to innovation.
As part of its commitment to innovation, Making Science offers its clients end-to-end capabilities required for consulting, development, integration and maintenance of advanced IT solutions that offer maximum scalability, cost-effectiveness and efficiency. In addition, it has a global network of delivery hubs that drive job creation and the availability of highly qualified technological talent for the development of projects that accelerate transformation and modernization.
Making Science participates in various ESG initiatives, including the Climate Pledge, the United Nations Global Compact and the Pledge1% initiative, supporting non-profit organisations in its community with a strong commitment that will have a great impact in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122293551/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom